PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1488039
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1488039
Antifungal Drugs Market - By Drug Class (Azoles, Echinocandins), Indication (Candidiasis, Aspergillosis), Infection Type (Systemic, Superficial), Route of Administration, Medication, Type, Distribution Channel & Forecast 2024 - 2032
Antifungal Drugs Market size is projected to expand at 3.7% CAGR from 2024 to 2032. The increasing incidence of fungal infections, particularly among immunocompromised patients and those with chronic conditions, such as HIV/AIDS, cancer, and diabetes is accelerating the demand for antifungal medications.
Significant innovations in drug development, including the introduction of novel antifungal agents and combination therapies are increasing the penetration of these drugs. For instance, in January 2024, Fresenius Kabi, a global healthcare company, launched Posaconazole Injection, a generic alternative to Noxafil(R), for the treatment or prevention of severe fungal infections in immunocompromised adults and children.
The expanding geriatric population, rising awareness about fungal infections, and improving healthcare infrastructure in emerging economies are further accelerating the product appeal. The growing prevalence of antifungal resistance and the emergence of new fungal strains is further underscoring the need for innovative treatment options, driving R&D investments in antifungal drugs.
The overall industry is segregated into drug class, indication, infection type, route of administration, medication, type, distribution channel, and region.
In terms of drug class, the market size from the polyenes segment is estimated to rise at 2.9% CAGR from 2024 to 2032. This is due to the effectiveness of polyene drugs, such as amphotericin B in treating severe and systemic fungal infections. The broad-spectrum activity and established efficacy of polyenes against a wide range of fungal pathogens is also contributing to their continued use as first-line treatments.
Based on infection type, the antifungal drugs market from the superficial antifungal infections segment is anticipated to expand at 5.3% CAGR through 2032. The increasing prevalence of superficial fungal infections like athlete's foot, ringworm, and fungal nail infections is driving the demand for topical antifungal medications. The availability of OTC antifungal treatments and the rising awareness about the importance of early treatment will also drive the segment growth.
Regionally, the Asia Pacific antifungal drugs market is estimated to expand at 4.3% CAGR from 2024 to 2032. This can be credited to the large and growing population, increasing incidence of fungal infections, and expanding healthcare infrastructure. The rising awareness about fungal diseases and improving access to healthcare services is driving the appeal of antifungal drugs. The growing adoption of antifungal medications in emerging economies and hefty investments in the formulation of new drugs will favor the regional industry growth.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast parameters
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of fungal infections
- 3.2.1.2 Rising awareness and adoption of antifungal drugs
- 3.2.1.3 Increasing R&D activities for developing novel antifungal drugs
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Increasing antifungal drug resistance
- 3.2.2.2 Increasing product recalls
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Pipeline analysis
- 3.5 Regulatory landscape
- 3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Azoles
- 5.3 Echinocandins
- 5.4 Polyenes
- 5.5 Allylamines
- 5.6 Other drug classes
Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Dermatophytosis
- 6.3 Aspergillosis
- 6.4 Candidiasis
- 6.5 Mucormycosis
- 6.6 Other indications
Chapter 7 Market Estimates and Forecast, By Infection Type, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Systemic antifungal infections
- 7.3 Superficial antifungal infections
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Oral
- 8.3 Topical
- 8.4 Injectable
Chapter 9 Market Estimates and Forecast, By Medication, 2018 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 Prescription
- 9.3 OTC
Chapter 10 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)
- 10.1 Key trends
- 10.2 Branded
- 10.3 Generic
Chapter 11 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)
- 11.1 Key trends
- 11.2 Hospital pharmacies
- 11.3 Retail pharmacies
- 11.4 Online pharmacies
Chapter 12 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 12.1 Key trends
- 12.2 North America
- 12.2.1 U.S.
- 12.2.2 Canada
- 12.3 Europe
- 12.3.1 Germany
- 12.3.2 UK
- 12.3.3 France
- 12.3.4 Spain
- 12.3.5 Italy
- 12.3.6 Rest of Europe
- 12.4 Asia Pacific
- 12.4.1 China
- 12.4.2 Japan
- 12.4.3 India
- 12.4.4 Australia
- 12.4.5 Rest of Asia Pacific
- 12.5 Latin America
- 12.5.1 Brazil
- 12.5.2 Mexico
- 12.5.3 Rest of Latin America
- 12.6 Middle East and Africa
- 12.6.1 South Africa
- 12.6.2 Saudi Arabia
- 12.6.3 Rest of Middle East and Africa
Chapter 13 Company Profiles
- 13.1 Abbott Laboratories
- 13.2 Astellas Pharma, Inc.
- 13.3 Bayer AG
- 13.4 Enzon Pharmaceuticals, Inc.
- 13.5 GlaxoSmithKline plc
- 13.6 Glenmark
- 13.7 Merck & Co., Inc.
- 13.8 Novartis AG
- 13.9 Pfizer, Inc.
- 13.10 Sanofi
